Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7050437 | 0.88 | NPC1 (0.54) | NPC1RAB9APOLBCASP3MGLL | |
| SCHEMBL30522295 | 0.82 | NPC1 (0.69) | NPC1RAB9APOLBCASP3MGLL | |
| SCHEMBL2233522 | 0.82 | NPC1 (0.69) | NPC1RAB9APOLBCASP3MGLL | |
| SCHEMBL16193532 | 0.82 | NPC1 (0.69) | NPC1RAB9APOLBCASP3MGLL | |
| SCHEMBL4291027 | 0.81 | NPC1 (0.64) | NPC1RAB9APOLBCASP3MGLL | |
| SCHEMBL9687318 | 0.81 | NPC1 (0.76) | NPC1RAB9APOLBCASP3MGLL | |
| SCHEMBL30207803 | 0.81 | NPC1 (0.68) | NPC1RAB9APOLBCASP3MGLL | |
| SCHEMBL17420472 | 0.81 | NPC1 (0.68) | NPC1RAB9APOLBCASP3MGLL | |
| SCHEMBL5853278 | 0.81 | NPC1 (1.00) | NPC1RAB9APOLBCASP3MGLL | |
| SCHEMBL3782118 | 0.81 | NPC1 (0.68) | NPC1RAB9APOLBCASP3MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6630512-B2 | Antiinflammatory agents; autoimmune disease | BIOGEN, INC. | 2003-10-07 | — | — | US | claimed |
| US-6624152-B2 | Inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention relates to pharmaceutical formulations comprising these compounds and methods of using them for inflammatory and autoimmune diseases | BIOGEN, INC. | 2003-09-23 | — | — | US | claimed |
| US-20030083267-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2003-05-01 | — | — | US | claimed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | claimed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | claimed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | claimed |
| US-6306840-B1 | ANTISTICKING AGENTS OF OLIGOPEPTIDES | BIOGEN, INC. | 2001-10-23 | — | — | US | claimed |
| EP-1060178-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER INC. (US) | 2000-12-20 | — | — | EP | claimed |
| WO-1999045006-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER INC. (US) | 1999-09-10 | — | — | WO | claimed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | claimed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | claimed |
| US-4067866-A | Process for preparing cephalosporins and certain novel 2β-thiohydrazo-azetidinones as intermediates | SOCIETA' FARMACEUTICI ITALIA (IT) | 1978-01-10 | — | — | US | claimed |
| EP-3765447-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | Kezar Life Sciences (US) | 2021-01-20 | — | — | EP | disclosed |
| WO-2019178510-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2019-09-19 | — | — | WO | disclosed |
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| EP-0945448-B1 | 5-ALKOXY-2(3H)-OXAZOLONE COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | UBE INDUSTRIES (JP) | 2008-11-26 | — | — | EP | disclosed |
| US-6020496-A | 5-alkoxy-2(3H)-oxazolone compounds and process for preparing the same | UBE INDUSTRIES, LTD. (JP) | 2000-02-01 | — | — | US | disclosed |
| EP-0945448-A1 | 5-ALKOXY-2(3H)-OXAZOLONE COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | UBE INDUSTRIES, LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083267-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | NPC1 2649/4885RAB9A 1779/4885POLB 4750/4885 |
| US-20030018016-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | NPC1 2649/4885RAB9A 1779/4885POLB 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.